Orna is eligible to receive up to $3.5 billion in the partnership if it hits sales and development goals for the vaccine and therapeutics programs. Merck is also investing $100 million into Orna Therapeutics’ latest series B financing round, according to the Aug. 16 press release.
“This broad strategic collaboration brings together Merck’s significant expertise in nucleic acid biology, clinical development, and manufacturing with Orna’s compelling circular RNA technology to explore the opportunity to develop a new generation of potential vaccines and therapeutics,” said Fiona Marshall, PhD, senior vice president and head of discovery, preclinical and translational medicine at Merck Research Laboratories. “We look forward to working with the talented scientific and technical teams at Orna.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
